DOAC Formulary Review Service

The MMS service is a clinical therapy review service aligned to support local and national guidance in relation to the prescribing of best value DOAC therapy.

The review of high cost DOAC prescribing will be delivered in line with a focus as detailed below:

• Screen to highlight patients prescribed high cost DOAC for stroke prevention in AF

• Screen CrCl and weights to establish if current DOAC dosing is appropriate

• Cohort reviewed to optimise and potentially change DOAC to a low-cost generic option eg. rivaroxaban or apixaban

Please complete the form below to request a virtual meeting and receive further information in relation to the service offer.